阿莫西林/克拉维酸钾治疗下呼吸道感染临床观察  

Efficacy of amoxicillin/clavulanate potassium in treating lower respiratory tract infection

作　　者：王迎春[1] 庄伟清[1] 潘雪晖[1] 

机构地区：[1]北京大学深圳医院药剂科,广东深圳518036

出　　处：《安徽医药》2006年第1期17-18,共2页Anhui Medical and Pharmaceutical Journal

摘　　要：目的 观察阿莫西林／克拉维酸钾治疗下呼吸道感染的临床疗效。方法 70例下呼吸道感染患者随机分为治疗组和对照组各35例，分别滴注阿莫西林／克拉维酸钾（实验组）1．8g或头孢噻肟钠4g（对照组），每日2次，共7～14d。结果：治疗组痊愈27例，显效3例，进步2例，总有效率91．4％；对照组痊愈28例，显效1例，进步3例，总有效率91．4％。两组有效率比较无显著性差异（χ^2=0．2647，P〉0．05）。不良反应发生率分别为8．5％和5．7％。结论 阿莫西林／克拉维酸钾治疗下呼吸道感染安全、有效的。Aim To study the therapeutical efficacy of amoxicillin/clavulanate potassium injection in treating lower respiratory tract infection by comparing with the efficacy of cefotaxime sodium injection. Methods A total of 70 patients were randomly divided into two groups：35 patients in the treatment group received amoxicillin/clavulanate potassium injection 1.8g bid;30 patients as the control group received cefotaxime sodium injection 4g bid,both for 7 ～ 14 days. Result Effective rate of the treatment group was 91.4%, and that of the control group was 91.4%. There was no statistically significant difference （ P 〉 0.05）. Side-effective rate was 8.5% and 5.7% respectively. Conclusion Amoxicillin/clavulanate potassium has a good therapeutical effect in treating lower respiratory tract infection with safety.

关 键 词：阿莫西林/克拉维酸钾 头孢噻肟钠 下呼吸道感染 临床疗效 

分 类 号：R56[医药卫生—呼吸系统]